Navigation Links
Patient's own infection-fighting T cells put late-stage melanoma into long-term remission
Date:6/18/2008

SEATTLE Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

Yee and colleagues removed CD4+ T cells, a type of white blood cell, from a 52-year-old man whose Stage 4 melanoma had spread to a groin lymph node and to a lung. T cells specific to targeting the melanoma were then expanded vastly in the laboratory using modifications to existing methods. The lab-grown cells were then infused into the patient with no additional pre- or post-conditioning therapies, such as growth-factor or cytokine treatment. Two months later, PET and CT scans revealed no tumors. The patient remained disease free two years later, when he was last checked.

"We were surprised by the anti-tumor effect of these CD4 T cells and its duration of response," Yee said. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study."

Yee cautioned that these results, presented in the journal's "Brief Report" section, represent only one patient with a specific type of immune system whose tumor cells expressed a specific antigen. More studies are needed to confirm the effectiveness of the experimental T-cell therapy. If proven successful in more patients, Yee predicted this therapy could be used for the 25 percent of all late-stage melanoma patients who have the same immune-system type and tumor antigen.

Using a patient's own immune system to combat cancer, called immunotherapy, is a growing area of research that aims to develop less-toxic cancer treatments than standard chemotherapy and radiation.

The patient in the journal report was one of nine patients with metastatic melanoma who were being treated in a recently completed clinical trial to test dose- escalation of autologous CD4+ T cells. Earlier studies performed by Yee used CD8+ T cells, which do not persist in the body without the support of CD4+ T cells or growth factors such as interleukin 2. Yee and colleagues theorized that infusion of a massive dose of CD4+ T cells would persist longer in the body because they make their own growth factor, interleukin 2, while stimulating the anti-tumor effect of the patient's existing CD8+ T cells. However, until recently there was no feasible way to isolate and expand anti-tumor CD4+ T cells in the lab.

The researchers were successful in all of these areas. The patient received a dose of 5 billion cloned CD4+ T cells with specificity for the melanoma-associated NY-ESO-1 antigen. The cells persisted for at least 80 days in the patient's body. And, even though only 50 percent to 75 percent of the patient's tumor cells expressed the NY-ESO-1 antigen, the entire tumor regressed following the infusion. The scientists postulated that the patient's immune response was broadened to other antigens expressed by the tumor cells. Follow-up tests showed T-cell responses to two additional tumor antigens, MAGE-3 and MART-1.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. World Renowned Hand Surgeon Helps Patients Conquer Joint Discomfort Naturally
2. FDA Panel Recommends Enbrel for Pediatric Patients
3. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
4. Medicsight ColonCAD Technology Successfully Identified Cancer in 100% of Patients Included in Data Presented at ESGAR 2008
5. Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance
6. Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
7. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
8. Same-day pregnancy test provides valuable guidance to pre-surgery patients
9. Future hope for patients with breast cancers resistant to tamoxifen
10. Some patients may not need insulin for long-term control of type 2 diabetes
11. Nurses, Doctors, Patients to Protest Health Insurers at National Day of Action - June 19th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... San Rafael, CA (PRWEB) , ... February 12, 2016 , ... ... camps outside Des Moines, Iowa. Legacy Golf Club, located in Norwalk, serves as the ... Teacher of the Year, Rob Randall. , “We have had successful camps in recent ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging ... field of long term care. With that, says Patrick Loughney, president of ... administrative roles in long term care environments. His company, which offers prep courses ...
(Date:2/12/2016)... ... February 12, 2016 , ... With the exception of restorative dentistry, to date there ... With the recent approval by the FDA, there is a now a new protocol ... varnish, SDF is very simple and quick to apply. The application is as simple ...
(Date:2/11/2016)... Los Angeles, CA (PRWEB) , ... February 11, 2016 , ... ... Weight Loss System, a product marketed as a weight loss dietary supplement, is being ... Angeles medical group Beverly Hills Physicians, because there is not a single supplement on ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... performing a wide range of cosmetic procedures. Along with performing procedures, the magazine ... and results of many cosmetic procedures. One of the most common procedures he ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Conn. , Feb. 11, 2016  AfterPill.com is ... to recommend alcohol abstinence for all women who are ... in the U.S. each year and raises the risks ... --> --> According to the Guttmacher ... 70% of women of child-bearing age, who have sex ...
(Date:2/11/2016)... , 11 de fevereiro de 2016  A ... sua fábrica de soroalbumina bovina (BSA -- ... fábrica fica na Ilha Norte da Nova Zelândia, ... e estabelecido na fábrica da Proliant nos EUA, ... O projeto e instalação dos equipamentos foram feitos ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016 /PRNewswire/ ... people, but for those with type 1 diabetes, the ... students juggle class schedules, assignments and campus activities, they ... 1 diabetes. On top of that, many are living ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders ...
Breaking Medicine Technology: